iGMDRD605

Canonical SMILES: CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4

InChI: InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1

InChI Key: IRTDIKMSKMREGO-OAHLLOKOSA-N

Loading, please wait...
Standard Name
Pubchem CID
Drug Status
Drug Type
Standard NameAZD6482
Pubchem CID44137700
Drug StatusAlone
Drug TypeSmall Molecule

Drug Targets:

PI3KbetaPIK3CD

Drug Pathways:

PI3K/MTOR signaling

Drug-model tissue-cancer distribution: Bubble Plot

BREAStissue: BREAS cancer: BREAST model num: 0BREASTtissue: BREAST cancer: undefined model num: 2BREASTtissue: BREAST cancer: Breast Carcinoma model num: 2BLOOtissue: BLOO cancer: BLOOD model num: 0BLOODtissue: BLOOD cancer: undefined model num: 1undefinetissue: undefine cancer: undefined model num: 0undefinedtissue: undefined cancer: PANCAN model num: 26BOWEtissue: BOWE cancer: BOWEL model num: 0BOWELtissue: BOWEL cancer: undefined model num: 1UTERUtissue: UTERU cancer: UTERUS model num: 0UTERUStissue: UTERUS cancer: undefined model num: 1LYMPtissue: LYMP cancer: LYMPH model num: 0LYMPHtissue: LYMPH cancer: Diffuse Large B-Cell Lymphoma (DLBCL) model num: 2BRAItissue: BRAI cancer: BRAIN model num: 0BRAINtissue: BRAIN cancer: Glioblastoma Multiforme (GBM) model num: 2HEAD_NECtissue: HEAD_NEC cancer: HEAD_NECK model num: 0HEAD_NECKtissue: HEAD_NECK cancer: Head and Neck Squamous Cell Carcinoma (HNSC) model num: 1KIDNEtissue: KIDNE cancer: KIDNEY model num: 0KIDNEYtissue: KIDNEY cancer: Renal Clear Cell Carcinoma (CCRCC) model num: 2SKItissue: SKI cancer: SKIN model num: 0SKINtissue: SKIN cancer: Cutaneous Melanoma (SKCM) model num: 1

Drug-gene pathway enrichments

Drug-gene GO enrichments

Drug-Gene: Aster Plot


Loading, please wait...
Gene ID
Gene Name
Model Num.
3845 KRAS 1
8289 ARID1A 1
6597 SMARCA4 1
1786 DNMT1 1
Showing 1 to 4 of 30 rows rows per page

Gene in drug-gene network: Network Plot

pluripotinpluripotindexamethasonedexamethasonePLX-4720PLX-4720Compound 1bCompound 1bNicotin-AmideNicotin-AmideEthyl L-asparaginateEthyl L-asparaginateASNSASNStipifarnib-P2tipifarnib-P2neopeltolideneopeltoliderotenonerotenoneBMS-536924BMS-536924brefeldin.Abrefeldin.Acytochalasin.Bcytochalasin.BBIX01294BIX01294ubistatin Bubistatin BBRD4132BRD4132SepantroniumSepantroniumJQ1 CompoundJQ1 CompoundVX-680VX-680tamatinibtamatinibpurmorphaminepurmorphaminezebularinezebularineChloropentafluorobenzeneChloropentafluorobenzenenutlin 3nutlin 3PemetrexedPemetrexedFANCGFANCGcetuximabcetuximabPI3K pathway inhibitors (alone or in combination)PI3K pathway inhibitors (alone or in combination)quinoclaminequinoclamineEverolimusEverolimusisoevodiamineisoevodiamineparbendazoleparbendazoletosedostattosedostatoligomycin.Aoligomycin.AML214ML214triptolidetriptolidePI3K pathway inhibitorsPI3K pathway inhibitorsBRD7137BRD7137BYL719 (Alpelisib)BYL719 (Alpelisib)trastuzumab alonetrastuzumab alonePIK3CAPIK3CAkinetin ribosidekinetin ribosideMST-312MST-312NSC95397NSC95397triacsin Ctriacsin CABT737ABT737BRD6368BRD6368austocystin.Daustocystin.Dnakiterpiosinnakiterpiosin(-)-gallocatechin-3-O-gallate(-)-gallocatechin-3-O-gallate179324-69-7179324-69-7pevonedistatpevonedistatSMARCA4SMARCA4PP-30PP-30selumetinib in BRAF mutant tumorsselumetinib in BRAF mutant tumorsMEK inhibitorsMEK inhibitorsGefitnibGefitnibCHEMBL399379CHEMBL399379ErlotinibErlotinibPanitumumabPanitumumabPD0325901PD0325901NSC141540NSC141540SarcolysinSarcolysinRefametinibRefametinibRegorafenibRegorafenibTrametinibTrametinibKRASKRASCDK4/6 inhibitorsCDK4/6 inhibitorsBMS-754807BMS-754807VER 155008VER 155008BI-2536BI-2536FedratinibFedratinibDabrafenibDabrafenibVemurafenibVemurafenibBinimetinib (MEK162)Binimetinib (MEK162)NRASNRASPertuzumabPertuzumabNeratinibNeratiniblapatinib in HER2-amplifiedlapatinib in HER2-amplifiedDacomitinibDacomitinibAfatnibAfatnibERBB2 TKIsERBB2 TKIsNsc 632839Nsc 632839chaetocinchaetocinchemotherapychemotherapyVorinostat (SAHA)Vorinostat (SAHA)PAC-1PAC-1Ado-trastuzumab emtansineAdo-trastuzumab emtansineERBB2ERBB2SN-38SN-38RITARITAserdemetanserdemetanGW-843682XGW-843682Xbistramide Abistramide ANVP-AUY922NVP-AUY922SCHEMBL2608041SCHEMBL2608041curcumincurcuminCD437CD437SMAD3SMAD3QuiflaponQuiflaponDactolisibDactolisibISX-9ISX-9ParthenolideParthenolideSR-II-138ASR-II-138AteniposideteniposideFqi1Fqi1KDM6AKDM6ACHIR-99021CHIR-99021fumonisin.B1fumonisin.B1LY 2183240LY 2183240penfluridolpenfluridolAM-580AM-580gossypolgossypolMK-2206MK-2206DNMT1DNMT1QL-XI-92QL-XI-92CCT007093CCT007093CH5424802CH5424802Avagacestat (BMS-708163)Avagacestat (BMS-708163)CHD4CHD4PRL-3 Inhibitor IPRL-3 Inhibitor IIdarubicinIdarubicinlovastatin acidlovastatin acidNPC26NPC26ursolic acidursolic acidindisulamindisulamFQI-2FQI-2MGAMGABX-795BX-795CIL55ACIL55AitraconazoleitraconazoleCompound.23.citrateCompound.23.citrate4-methylfasudil4-methylfasudilPIK3C2BPIK3C2Bleucascandrolide Aleucascandrolide AGMX1778GMX1778Tyrphostin AG 1478Tyrphostin AG 1478GemcitabineGemcitabineARID1AARID1AnavitoclaxnavitoclaxBRD63610BRD63610tankyrase inhibitorstankyrase inhibitorsSB225002SB225002kahalalide Fkahalalide FPROCPROCKU0060648KU0060648WWTR1WWTR1PD153035PD153035ABT-263ABT-263phloretinphloretinSNAI1SNAI1Merck60Merck60BRD4770BRD4770LexibulinLexibulinCHEK2CHEK2ZINC6718453ZINC6718453Liposomal DoxorubicinLiposomal DoxorubicinTGX221TGX221PF4708671PF4708671ZNF638ZNF638PIK3R3PIK3R3salermidesalermideCompound.7d.cisCompound.7d.cisBML-259BML-259ceruleninceruleninABT-751ABT-751rTRAILrTRAILCIL41CIL41TW-37TW-37SKI IISKI IIpiperlonguminepiperlongumineEIF4A2EIF4A2ELCPKELCPKPX 12PX 12ML 210ML 210tivozanibtivozanibML162ML162OlaparibOlaparibLCKLCKSirolimusSirolimusCHM-1CHM-1AFDNAFDNPI-103PI-103AZD-1775AZD-1775KMT2CKMT2CFK 866FK 866PRIMA-1PRIMA-1BIRB-796BIRB-796Compound 10b [PMID: 11504634]Compound 10b [PMID: 11504634](1S,3R)-RSL3(1S,3R)-RSL3Cis-PlatinCis-PlatinERCC4ERCC4LY3023414LY3023414GSK2636771GSK2636771Compound.1541ACompound.1541APARP inhibitorsPARP inhibitorsmTOR inhibitorsmTOR inhibitorsAZD8186AZD8186GSK690693GSK690693PTENPTENCompound 44Compound 44AZD-8055AZD-8055STF62247STF62247FOXP1FOXP1CobimetinibCobimetinibSorafenibSorafenibBRAF inhibitorsBRAF inhibitorspan-RAF inhibitorspan-RAF inhibitorsBRAFBRAFEP300EP300SL.0101.1SL.0101.1Fatostatin AFatostatin ABleomycin (50 uM)Bleomycin (50 uM)pifithrin-mupifithrin-muavrainvillamideavrainvillamideIOX2IOX2VEGFAVEGFAAZD6482.1AZD6482.1

Models in AZD6482

Model
Level
Reference ID
Tissue
Cancer
Drug
Clinical Response
Source
EXP(SMAD3) protein MCLP BREAST undefined AZD6482.1 sensitivity in vitro
EXP(SNAIL) protein MCLP BREAST undefined AZD6482.1 sensitivity in vitro
EXP(MTOR_pS2448) protein MCLP BLOOD undefined AZD6482 sensitivity in vitro
EXP(AKT_pS473) protein MCLP undefined PANCAN AZD6482 resistance in vitro
EXP(AKT_pS473) protein MCLP undefined PANCAN AZD6482.1 resistance in vitro
EXP(AKT_pT308) protein MCLP undefined PANCAN AZD6482.1 resistance in vitro
EXP(CMYC) protein MCLP undefined PANCAN AZD6482.1 sensitivity in vitro
EXP(CAVEOLIN1) protein MCLP undefined PANCAN AZD6482.1 resistance in vitro
EXP(LCK) protein MCLP undefined PANCAN AZD6482.1 sensitivity in vitro
EXP(TAZ) protein MCLP undefined PANCAN AZD6482.1 resistance in vitro
Showing 1 to 10 of 41 rows rows per page

​​​​

SITE
DATATYPES
CLASSFICATION
Map

Copyright © 2018 Modellab | All Rights Reserved

Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.